Portal de investigación
ESTUDIO ABIERTO, MULTICENTRICO, DE GRUPO UNICO, PARA ESTUDIAR LA SEGURIDAD Y EFICACIA DE POMALIDOMIDA (CC 4047) EN MONOTERAPIA EN PACIENTES CON MIELOMA MULTIPLE REFRACTARIO O RECIDIVANTE Y REFRACTARIO ESTUDIO COMPLEMENTARIO DEL ENSAYO CLINICO CC 4047 MM 0 03.
Datos básicos
- Código:
- CC-4047-MM-003-C
- Protocolo:
- CC-4047-MM-003-C
- EUDRACT:
- 2010-023343-16
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2011
- Año de finalización:
- 2013
Objetivos del proyecto
Observaciones: Estado Comité: FINALIZADO
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia].
Sanz MÁ; (...); Sociedad Española de Hematología y Oncología Pediátricas
Abstract of Published Item. 10.1016/j.medcli.2011.11.011. 2012
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
Zabaleta, Aintzane; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-184797. 2023
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Bergua Burgues, Juan Miguel; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189676. 2023
A new precision medicine test to guide personalized treatments decision for acute myeloid leukemia patients.
Ballesteros, J; (...); Robles, A
Meeting Abstract. 2017
A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E; (...); Montesinos P
Article. 10.1002/cncr.35618. 2024
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; (...); PETHEMA Group
Article. 10.1002/cncr.33403. 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Martinez-Cuadron, D; (...); Spanish PETHEMA group
Article. 10.1016/j.leukres.2018.11.006. 2019
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Bergua JM; (...); PETHEMA group
Article. 10.1111/bjh.14107. 2016
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Berard, Emilie; (...); Recher, Christian
Article. 10.1038/s41408-022-00700-x. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
Solana-Altabella A; (...); Montesinos P
Article. 10.1007/s00277-024-05891-w. 2024
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group
Article. 10.1016/j.leukres.2022.106821. 2022
Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients.
Article. 10.1007/s00277-012-1596-x. 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.
Pessoa de Magalhães RJ; (...); Orfao A
Article. 10.3324/haematol.2012.067272. 2013
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)
Bergua, J; (...); Montesinos, P
Meeting Abstract. 2018
Antifungal prophylaxis in the haematological patient: a practical approach.
Vázquez L; (...); Barberán J
Article. 2012
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.
Serrano, Josefina; (...); Montesinos, Pau
Article. 10.1016/j.jtct.2025.02.011. 2025
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.
Rosiñol L; (...); PETHEMA
Article. 10.3324/haematol.2011.051441. 2012
BRAF V600E mutation in adult acute lymphoblastic leukemia.
Alonso CM; (...); Sanz Alonso MA
Letter. 10.3109/10428194.2012.733878. 2013
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; (...); Spanish Pethema Group
Article. 10.3109/13693786.2012.693213. 2013
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Romero, Alejandra; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-163869. 2022
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)
Vicente, Navarro; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-190296. 2023
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal, Teresa; (...); Montesinos, Pau
Article. 10.1002/cam4.6120. 2023
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS
Saiz-Rodriguez, M.; (...); Labrador, J.
Meeting Abstract. 2020
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].
Rodríguez-Medina C; (...); Montesinos P
Correction. 10.1016/j.leukres.2020.106388. 2020
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.
Grau S; (...); Sanz MA
Article. 10.1186/1471-2334-12-83. 2012
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study
Kayser, S; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-111768. 2018
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Kayser S; (...); Levis MJ
Article. 10.3324/haematol.2021.278645. 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112974. 2018
Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Angenendt, L; (...); Schliemann, C
Article. 10.1200/JCO.19.00416. 2019
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Spanish PETHEMA Grp
Article. 10.4084/MJHID.2019.016. 2019
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU; (...); Montesinos P
Article. 10.1007/s00277-024-05840-7. 2024
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/17512433.2023.2174523. 2023
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.1007/s00277-020-04186-0. 2020
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/14728214.2021.2009800. 2022
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2011-0391. 2012
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador, Jorge; (...); Montesinos, Pau
Article. 10.1002/cncr.35431. 2024
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; (...); Gutiérrez NC
Article. 10.3324/haematol.2011.060780. 2012
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Ballesta-López O; (...); Montesinos P
Review. 10.2217/fon-2020-0700. 2020
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Helicobacter pylori in the diagnosis, treatment and follow-up of primary immune thrombocytopenia in Spain Reply
Jarque, Isidro, Sanz, Miguel A.
Article. 10.1016/j.medcli.2012.11.002. 2013
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Paiva B; (...); PETHEMA
Article. 10.1182/blood-2011-07-370460. 2012
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112495. 2018
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia
Barba P; (...); Ribera JM
Article. 10.3109/10428194.2015.1014365. 2015
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, Sabine; (...); Schlenk, Richard F.
Article. 10.3324/haematol.2022.282127. 2023
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E; (...); Ayala R
Article. 10.1111/bjh.16432. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Pinana JL; (...); Sanz MA
Article. 10.1007/s00277-013-1872-4. 2014
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; (...); Aliño SF
Article. 10.1124/dmd.112.047977. 2013
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study
Boluda, Blanca; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD
De la Fuente, A.; (...); Montesinos, P.
Meeting Abstract. 2019
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; (...); de la Rubia J
Article. 10.1016/j.bbmt.2012.08.009. 2013
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; (...); San Miguel JF
Article. 10.1056/NEJMoa1300439. 2013
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1038/leu.2017.178. 2018
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato
Article. 10.1016/j.jtct.2020.12.029. 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Recher, Christian; (...); Montesinos, Pau
Article. 10.1038/s41375-021-01425-9. 2022
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; (...); Zeidan AM
Article. 10.1038/s41375-020-0783-3. 2020
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; (...); Montesinos P
Article. 10.1182/bloodadvances.2020003195. 2021
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas, Claudia; (...); On Behalf Of Pethema Group
Article. 10.3390/cancers15020438. 2023
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Paiva B; (...); San Miguel JF
Article. 10.1016/j.ajpath.2012.07.020. 2012
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES
Primo, D.; (...); Ballesteros, J.
Meeting Abstract. 2017
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
Montesinos, P.; (...); Sanz, M.
Meeting Abstract. 2017
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; (...); Giebel S
Article. 10.1016/j.clml.2019.09.616. 2020
Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.
Rojas R; (...); Torres A
Article. 10.4084/MJHID.2012.011. 2012
Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Kayser S; (...); Montesinos P
Article. 10.1038/s41375-020-0758-4. 2020
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Article. 10.3324/haematol.2022.282506. 2024
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Shallis, RM; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-119755. 2018
Paclitaxel and carboplatin treatment for advanced ovarian cancer during pregnancy.
Ruiz Ramos J; (...); Poveda JL
Article. 10.1159/000360691. 2013
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Rodriguez-Medina, C; (...); Fernandez, PM
Article. 10.1016/j.leukres.2020.106352. 2020
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine
Bennett TA; (...); Ballesteros J
Article. 10.1016/j.clml.2013.11.006. 2014
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1007/s00277-013-1914-y. 2014
PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review
Sobas, M; (...); Montesinos, P
Review. 10.3390/cancers12051313. 2020
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1007/s40261-019-00881-7. 2020
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1080/17474086.2020.1818559. 2020
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments
Ballesteros, J; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-115849. 2018
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
Uriel Suarez, Edwin; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-167365. 2022
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA
LLop, M.; (...); Angel Sanz, M.
Article. 2013
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; (...); Sanz MA
Article. 10.1016/j.jmoldx.2012.06.006. 2012
Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O; (...); PETHEMA and PALG Groups
Article. 10.1080/10428194.2019.1607327. 2019
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
Renal Transplantation Recipients with AA Genotype in SNP rs4244285 of CYP2C19 Show An Increase in Hospital Stay Duration and Allograft Dysfunction Probably Due to Increased Tacrolimus Levels Caused by Interaction with Omeprazol
Boso, V; (...); Alino, S. F.
Article. 10.1097/00007890-201211271-01757. 2012
Role of autologous bone marrow transplant in multiple myeloma.
Article. 10.1097/CCO.0b013e328358f686. 2012
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
Paiva, B; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-113299. 2018
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
Robak T; (...); Petersen J
Article. 10.1182/blood-2012-06-438804. 2012
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1007/s00277-018-3304-y. 2018
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Vives, Susana; (...); PETHEMA Grp
Article. 10.3390/cancers16234028. 2024
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Espinoza, Marcela; (...); Martinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-185288. 2023
Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: implementation and outcomes of a new chemotherapy protocol.
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/1078155212457964. 2013
Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry
Tura, G. Teixido; (...); Cabrera, F.
Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Rosiñol L; (...); Programa para el Estudio y la Terapéutica de las Hemopatías Malignas
Article. 10.1182/blood-2012-02-408922. 2012
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E; (...); Zabaleta A
Article. 10.1182/bloodadvances.2024013212. 2024
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment
Montesinos P; (...); Sanz MÁ
Article. 10.1016/j.riam.2014.10.003. 2015
Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; (...); Vallejo C
Article. 2013
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189800. 2023
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
Lloret-Madrid, Pilar; (...); Montesinos, Pau
Article. 10.1002/cncr.35696. 2025
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1016/j.blre.2020.100675. 2020
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP; (...); Montesinos P
Letter. 10.3324/haematol.2023.284601. 2024
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
Montesinos, P; (...); Sanz, MA
Meeting Abstract. 2017
WT1 isoform expression pattern in acute myeloid leukemia.
Article. 10.1016/j.leukres.2013.10.009. 2013